tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncowebtumors-277Research ArticleСтатьиБИОПСИЯ СИГНАЛЬНЫХ ЛИМФАТИЧЕСКИХ УЗЛОВ ПРИ РАКЕ МОЛОЧНОЙ ЖЕЛЕЗЫКриворотькоП. В.KrivorotkoP. V.ДашянГ. А.DashyanG. A.ПалтуевР. М.PaltuevR. M.ЗерновК. Ю.ZernovK. U.БессоновА. А.BessonovA. A.ТабагуаТ. Т.TabaguaT. T.КомяховА. В.KomiahovА. V.ИвановаО. А.IvanovaO. А.ЖильцоваЕ. К.ZhiltsovaЕ. K.ВоротниковВ. В.VorotnikovV. V.НиколаевК. С.NikolaevK. S.ТруфановаЕ. С.TrufanovaE. S.ГиголаеваЛ. П.GigolaevaL. P.ХаджиматоваШ. М.HadjimatovaSh. M.БелобородоваК. А.BeloborodovaK. A.АртемьеваА. С.ArtemievaA. S.БуськоЕ. А.BuskoE. A.НовиковС. Н.NovikovS. N.КанаевС. В.KanaevS. V.СемиглазовВ. Ф.SemiglazovV. F.Научно-исследовательский институт онкологии имени Н. Н. ПетроваRussian Federation20161711201604s148Copyright © Криворотько П.В., Дашян Г.А., Палтуев Р.М., Зернов К.Ю., Бессонов А.А., Табагуа Т.Т., Комяхов А.В., Иванова О.А., Жильцова Е.К., Воротников В.В., Николаев К.С., Труфанова Е.С., Гиголаева Л.П., Хаджиматова Ш.М., Белобородова К.А., Артемьева А.С., Бусько Е.А., Новиков С.Н., Канаев С.В., Семиглазов В.Ф., 20162016Криворотько П.В., Дашян Г.А., Палтуев Р.М., Зернов К.Ю., Бессонов А.А., Табагуа Т.Т., Комяхов А.В., Иванова О.А., Жильцова Е.К., Воротников В.В., Николаев К.С., Труфанова Е.С., Гиголаева Л.П., Хаджиматова Ш.М., Белобородова К.А., Артемьева А.С., Бусько Е.А., Новиков С.Н., Канаев С.В., Семиглазов В.Ф.Krivorotko P.V., Dashyan G.A., Paltuev R.M., Zernov K.U., Bessonov A.A., Tabagua T.T., Komiahov А.V., Ivanova O.А., Zhiltsova Е.K., Vorotnikov V.V., Nikolaev K.S., Trufanova E.S., Gigolaeva L.P., Hadjimatova S.M., Beloborodova K.A., Artemieva A.S., Busko E.A., Novikov S.N., Kanaev S.V., Semiglazov V.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/277рак молочной железыбиопсия сигнальных лимфоузловReferencesДашян Г. А., Криворотько П. В., Новиков С. Н., Крживицкий П. И., Донских Р. В., Рогачев М. В., Брянцева Ж. В., Труфанова Е.С, Канаев С. В., Семиглазов В. Ф. Биопсия сигнальных лимфатических узлов при раке молочной железы. Учебно-методическое пособие, СПб.: НИИ онкологии имени Н. Н. Петрова, 2015. – С. 17–30.Дашян Г. А., Криворотько П. В., Новиков С. Н., Крживицкий П. И., Донских Р. В., Рогачев М. В., Брянцева Ж. В., Труфанова Е.С, Канаев С. В., Семиглазов В. Ф. Биопсия сигнальных лимфатических узлов при раке молочной железы. Учебно-методическое пособие, СПб.: НИИ онкологии имени Н. Н. Петрова, 2015. – С. 17–30.Канаев С. В., Новиков С. Н., Крживицкий П. И., Криворотько П. В., Семиглазов В. Ф., Ильин Н. Д., Брянцева Ж. В. Возможности ОФЭКТ-КТ в диагностике опухолевого поражения подмышечных лимфоузлов у больных раком молочной железы. Вопросы онкологии, 2014. N2. – C.51–56.Канаев С. В., Новиков С. Н., Крживицкий П. И., Криворотько П. В., Семиглазов В. Ф., Ильин Н. Д., Брянцева Ж. В. Возможности ОФЭКТ-КТ в диагностике опухолевого поражения подмышечных лимфоузлов у больных раком молочной железы. Вопросы онкологии, 2014. N2. – C.51–56.Семиглазов В. Ф., Канаев С. В., Криворотько П. В., Новиков С. Н., Жукова Л. А., Крживицкий П.И, Методические вопросы биопсии сигнальных лимфоузлов у больных раком молочной железы. Вопросы онкологии. 2013. Т. 59. № 2. С. 90–94.Семиглазов В. Ф., Канаев С. В., Криворотько П. В., Новиков С. Н., Жукова Л. А., Крживицкий П.И, Методические вопросы биопсии сигнальных лимфоузлов у больных раком молочной железы. Вопросы онкологии. 2013. Т. 59. № 2. С. 90–94.Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391–8. discussion 398–01.Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391–8. discussion 398–01.Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA. 2011;305:569–575.Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA. 2011;305:569–575.Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–933.Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–933.Canavese G, Catturich A, Vecchio C, Tomei D, Gipponi M, Villa G, Carli F, Bruzzi P, Dozin B. Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann Oncol. 2009;20:1001–1007.Canavese G, Catturich A, Vecchio C, Tomei D, Gipponi M, Villa G, Carli F, Bruzzi P, Dozin B. Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann Oncol. 2009;20:1001–1007.Purushotham AD, Upponi S, Klevesath MB, Bobrow L, Millar K, Myles JP, Duffy SW. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005;23:4312–4321.Purushotham AD, Upponi S, Klevesath MB, Bobrow L, Millar K, Myles JP, Duffy SW. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005;23:4312–4321.Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, et al. Sentinel lymph node biopsy in breast cancer: tenyear results of a randomized controlled study. Ann Surg. 2010;251:595–600.Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, et al. Sentinel lymph node biopsy in breast cancer: tenyear results of a randomized controlled study. Ann Surg. 2010;251:595–600.Fleissig A, Fallowfield LJ, Langridge CI, Johnson L, Newcombe RG, Dixon JM, Kissin M, Mansel RE. Post- operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat. 2006;95:279–293.Fleissig A, Fallowfield LJ, Langridge CI, Johnson L, Newcombe RG, Dixon JM, Kissin M, Mansel RE. Post- operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat. 2006;95:279–293.Zavagno G, De Salvo GL, Scalco G, Bozza F, Barutta L, Del Bianco P, Renier M, Racano C, Carraro P, Nitti D, GIVOM Trialists A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg. 2008;247:207–213.Zavagno G, De Salvo GL, Scalco G, Bozza F, Barutta L, Del Bianco P, Renier M, Racano C, Carraro P, Nitti D, GIVOM Trialists A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg. 2008;247:207–213.Yen TW, Hunt KK, Ross MI, Mirza NQ, Babiera GV, Meric- Bernstam F, Singletary SE, Symmans WF, Giordano SH, Feig BW, Ames FC, Kuerer HM. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005;200:516–26.Yen TW, Hunt KK, Ross MI, Mirza NQ, Babiera GV, Meric- Bernstam F, Singletary SE, Symmans WF, Giordano SH, Feig BW, Ames FC, Kuerer HM. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005;200:516–26.Intra, Mattia MD, Rotmensz, Nicole MSc, Veronesi, Paolo MD, Colleoni, Marco MD, Iodice, Simona MSc, Paganelli, Giovanni MD, Viale, Giuseppe MD, FRCPath, Veronesi, Umberto MD. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European Institute of Oncology on 854 patients in 10 years. Ann Surg. 2008;247:315–9.Intra, Mattia MD, Rotmensz, Nicole MSc, Veronesi, Paolo MD, Colleoni, Marco MD, Iodice, Simona MSc, Paganelli, Giovanni MD, Viale, Giuseppe MD, FRCPath, Veronesi, Umberto MD. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European Institute of Oncology on 854 patients in 10 years. Ann Surg. 2008;247:315–9.Jackman RJ, Burbank F, Parker SH, Evans WP, 3rd, Lechner MC, Richardson TR, Smid AA, Borofsky HB, Lee CH, Goldstein HM, Schilling KJ, Wray AB, Brem RF, Helbich TH, Lehrer DE, Adler SJ. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology. 2001;218:497–502.Jackman RJ, Burbank F, Parker SH, Evans WP, 3rd, Lechner MC, Richardson TR, Smid AA, Borofsky HB, Lee CH, Goldstein HM, Schilling KJ, Wray AB, Brem RF, Helbich TH, Lehrer DE, Adler SJ. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology. 2001;218:497–502.Cox CE, Cox JM, Ramos D, Meade TL. Intramammary sentinel lymph nodes: what is the clinical significance? Ann Surg Oncol. 2008;15:1273–4.Cox CE, Cox JM, Ramos D, Meade TL. Intramammary sentinel lymph nodes: what is the clinical significance? Ann Surg Oncol. 2008;15:1273–4.Galimberti V, Veronesi P, et al. Stage migration after biopsy of internal mammary chain lymph nodes in breast cancer patients. Ann Surg Oncol. 2002;9:924–8.Galimberti V, Veronesi P, et al. Stage migration after biopsy of internal mammary chain lymph nodes in breast cancer patients. Ann Surg Oncol. 2002;9:924–8.Intra M, Garcia-Etienne CA, Renne G, Trifir G, Rotmensz N, Gentilini OD, Galimberti V, Sagona A, Mattar D, Sangalli C, Gatti G, Luini A, Veronesi U. When sentinel lymph node is intramammary. Ann Surg Oncol. 2008;15:1304–8.Intra M, Garcia-Etienne CA, Renne G, Trifir G, Rotmensz N, Gentilini OD, Galimberti V, Sagona A, Mattar D, Sangalli C, Gatti G, Luini A, Veronesi U. When sentinel lymph node is intramammary. Ann Surg Oncol. 2008;15:1304–8.Shrenk P, Wayand W. Sentinel-node biopsy in axillary lymph- node staging for patients with multicentric breast cancer. Lancet. 2001;357:122.Shrenk P, Wayand W. Sentinel-node biopsy in axillary lymph- node staging for patients with multicentric breast cancer. Lancet. 2001;357:122.Kumar R, Jana S, Heiba SI, Dakhel M, Axelrod D, Siegal B, et al. Retrospective analysis of sentinel node localization in multifocal, multi-centric, palpable, or non palpable breast cancer. J Nucl Med. 2003;44:7–10.Kumar R, Jana S, Heiba SI, Dakhel M, Axelrod D, Siegal B, et al. Retrospective analysis of sentinel node localization in multifocal, multi-centric, palpable, or non palpable breast cancer. J Nucl Med. 2003;44:7–10.Gentilini O, Trifir G, Soteldo J, Luini A, Intra M, Galimberti V, Veronesi P, Silva L, Gandini S, Paganelli G, Veronesi U. Sentinel lymph node biopsy in multicentric breast cancer. The experience of the European Institute of Oncology. Eur J Surg Oncol. 2006;32:507–10.Gentilini O, Trifir G, Soteldo J, Luini A, Intra M, Galimberti V, Veronesi P, Silva L, Gandini S, Paganelli G, Veronesi U. Sentinel lymph node biopsy in multicentric breast cancer. The experience of the European Institute of Oncology. Eur J Surg Oncol. 2006;32:507–10.Viale G, Zurrida S, Maiorano E, Mazzarol G, Pruned G, Paganelli G, Maisonneuve P, Veronesi U. Predicting the status of axillary sentinel lymph nodes in 4,351 patients with invasive breast carcinoma treated in a single institution. Cancer. 2005;103:492–500.Viale G, Zurrida S, Maiorano E, Mazzarol G, Pruned G, Paganelli G, Maisonneuve P, Veronesi U. Predicting the status of axillary sentinel lymph nodes in 4,351 patients with invasive breast carcinoma treated in a single institution. Cancer. 2005;103:492–500.Intra M, Veronesi P, Gentilini OD, Trifir G, Berrettini A, Cecilio R, Colleoni M, Rietjens M, Luini A, Paganelli G, Veronesi U. Sentinel lymph node biopsy is feasible even after total mastectomy. J Surg Oncol. 2007;95(2):175–9. doi: 10.1002/jso.20670.Intra M, Veronesi P, Gentilini OD, Trifir G, Berrettini A, Cecilio R, Colleoni M, Rietjens M, Luini A, Paganelli G, Veronesi U. Sentinel lymph node biopsy is feasible even after total mastectomy. J Surg Oncol. 2007;95(2):175–9. doi: 10.1002/jso.20670.Rodriguez Fernandez J, Martella S, Trifir G, Caliskan M, Chifti C, Brenelli F, Botteri E, Rossetto F, Rotmensz N, Rietjens M, Veronesi P. Sentinel node biopsy in patients with previous breast aesthetic surgery. Ann Surg Oncol. 2009;16:989–92.Rodriguez Fernandez J, Martella S, Trifir G, Caliskan M, Chifti C, Brenelli F, Botteri E, Rossetto F, Rotmensz N, Rietjens M, Veronesi P. Sentinel node biopsy in patients with previous breast aesthetic surgery. Ann Surg Oncol. 2009;16:989–92.Intra M, Trifir G, Galimberti V, Gentilini O, Rotmensz N, Veronesi P. Second axillary sentinel node biopsy for ipsilateral breast tumour recurrence. Br J Surg. 2007;94:1216–9.Intra M, Trifir G, Galimberti V, Gentilini O, Rotmensz N, Veronesi P. Second axillary sentinel node biopsy for ipsilateral breast tumour recurrence. Br J Surg. 2007;94:1216–9.Gentilini O, Cremonesi M, Trifir G, Ferrari M, Baio SM, Caracciolo M, et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol. 2004;15:1348–51.Gentilini O, Cremonesi M, Trifir G, Ferrari M, Baio SM, Caracciolo M, et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol. 2004;15:1348–51.Gentilini O, Cremonesi M, Toesca A, Colombo N, Peccatori F, Sironi R, Sangalli C, Rotmensz N, Pedroli G, Viale G, Veronesi P, Galimberti V, Goldhirsch A, Veronesi U, Paganelli G. Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Mol Imaging. 2010;37:78–83.Gentilini O, Cremonesi M, Toesca A, Colombo N, Peccatori F, Sironi R, Sangalli C, Rotmensz N, Pedroli G, Viale G, Veronesi P, Galimberti V, Goldhirsch A, Veronesi U, Paganelli G. Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Mol Imaging. 2010;37:78–83.Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19:1508–1516.Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19:1508–1516.Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, et al.: NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines) Breast Cancer, version 1,2014.Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, et al.: NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines) Breast Cancer, version 1,2014.Members of the German AGO Breast Committee.: Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Guidelines of the AGO Breast Committee 2013.Members of the German AGO Breast Committee.: Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Guidelines of the AGO Breast Committee 2013.Kelly AM, Dwamena B, Cronin P, Carlos RC. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy: systematic review and meta analysis. Acad Radiol. 2009;16:551–563.Kelly AM, Dwamena B, Cronin P, Carlos RC. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy: systematic review and meta analysis. Acad Radiol. 2009;16:551–563.Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006;93:539–546.Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006;93:539–546.van Deurzen CH, Vriens BE, Tjan-Heijnen VC, van der Wall E, Albregts M, van Hilligersberg R, Monninkhof EM, van Diest PJ. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer. 2009;45:3124–3130.van Deurzen CH, Vriens BE, Tjan-Heijnen VC, van der Wall E, Albregts M, van Hilligersberg R, Monninkhof EM, van Diest PJ. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer. 2009;45:3124–3130.Tan VK, Goh BK, Fook-Chong S, Khin LW, Wong WK, Yong WS. The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis. J Surg Oncol. 2011;104:97–103.Tan VK, Goh BK, Fook-Chong S, Khin LW, Wong WK, Yong WS. The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis. J Surg Oncol. 2011;104:97–103.Morrow M, Dang CT. Sentinel node biopsy after neoadjuvant chemotherapy: a new standard for patients with axillary metastases? JAMA. 2013;310:1449–1450.Morrow M, Dang CT. Sentinel node biopsy after neoadjuvant chemotherapy: a new standard for patients with axillary metastases? JAMA. 2013;310:1449–1450.Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609–618.Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609–618.Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609–618.Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609–618.Gill G, SNAC Trial Group of the Royal Australasian College of Surgeons (RACS) and NHMRC Clinical Trials Centre Sentinel- lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol. 2009;16:266–275.Gill G, SNAC Trial Group of the Royal Australasian College of Surgeons (RACS) and NHMRC Clinical Trials Centre Sentinel- lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol. 2009;16:266–275.Wang Z, Wu LC, Chen JQ. Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis. Breast Cancer Res Treat. 2011;129:675–689.Wang Z, Wu LC, Chen JQ. Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis. Breast Cancer Res Treat. 2011;129:675–689.Rao R, Euhus D, Mayo HG, Balch C. Axillary node interventions in breast cancer: a systematic review. JAMA. 2013;310:1385–1394.Rao R, Euhus D, Mayo HG, Balch C. Axillary node interventions in breast cancer: a systematic review. JAMA. 2013;310:1385–1394.De Gournay E, Guyomard A, Coutant C, Boulet S, Arveux P, Causeret S, et al. Impact of sentinel biopsy on long-term quality of life in breast cancer patients. Br J Cancer. 2013;109:2783–2791.De Gournay E, Guyomard A, Coutant C, Boulet S, Arveux P, Causeret S, et al. Impact of sentinel biopsy on long-term quality of life in breast cancer patients. Br J Cancer. 2013;109:2783–2791.Veronesi U, Galimberti V, Paganelli G, Maisonneuve P, Viale G, Orecchia R, Luini A, Intra M, Veronesi P, Caldarella P, Renne G, Rotmensz N, Sangalli C, De Brito Lima L, Tullii M, Zurrida S. Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3,548 cases. Eur J Cancer. 2009;45:1381–8.Veronesi U, Galimberti V, Paganelli G, Maisonneuve P, Viale G, Orecchia R, Luini A, Intra M, Veronesi P, Caldarella P, Renne G, Rotmensz N, Sangalli C, De Brito Lima L, Tullii M, Zurrida S. Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3,548 cases. Eur J Cancer. 2009;45:1381–8.
The authors declare that there are no conflicts of interest present.